St. Jude's $167 Mil. Angio-Seal Puncture Closure Buy Adds $50 Mil. In Sales
This article was originally published in The Gray Sheet
Executive Summary
St. Jude's $167 mil. cash acquisition of marketing and manufacturing rights to Kensey Nash's Angio-Seal hemostatic puncture closure device from Tyco International would "more than double" sales into the cardiology cath lab by St. Jude's Daig division and add 60 to its sales and marketing staff, the firm states.
You may also be interested in...
Expanded AngioSeal Supply Deal Heightens Investor Interest In Kensey Nash
Kensey Nash's ability to convince investors that AngioSeal will generate sales exceeding $75 mil. over the life of a multi-year contract with St. Jude Medical helped the supplier's stock price swell by more than 11% during June
Expanded AngioSeal Supply Deal Heightens Investor Interest In Kensey Nash
Kensey Nash's ability to convince investors that AngioSeal will generate sales exceeding $75 mil. over the life of a multi-year contract with St. Jude Medical helped the supplier's stock price swell by more than 11% during June
Kensey Nash Extracts Biomaterials Growth To Curb Reliance On Angio-Seal
Kensey Nash likely will pursue an acquisition strategy and an expanded client base to leverage its biomaterial patents and manufacturing capability